Showing results (101-110 of 134) with videos related to
Sort By:
Pageof 14
Antiviral Research|September 17, 2011
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugsR Salpini, V Svicher, V Cento, et al.Journal of Medical Virology|April 17, 2013
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practiceR Salpini, C Alteri, V Cento, et al.HIV Medicine|March 19, 2010
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA)P Di Vincenzo, S Rusconi, F Adorni, et al.Microbiology Spectrum|January 30, 2024
Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infectionL Romani, F Del Chierico, S Pane, et al.Health Education Research|June 11, 2005
Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in MozambiqueM C Marazzi, M Bartolo, L Emberti Gialloreti, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 12, 2015
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of ItalyM Pollicita, C Alteri, M C Bellocchi, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 3, 2017
Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paperL Sarmati, M Andreoni, G Antonelli, et al.Infection|January 27, 2009
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patientsM M Santoro, A Bertoli, P Lorenzini, et al.The Journal of Antimicrobial Chemotherapy|December 26, 2015
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ARTS Lambert-Niclot, E C George, A Pozniak, et al.HIV Medicine|May 15, 2013
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analoguesM M Santoro, C Sabin, F Forbici, et al.Pageof 14